Press Releases May 27, 2026 06:50 AM

ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

ANI Pharmaceuticals CEO Nikhil Lalwani to Present at 2026 Jefferies Global Healthcare Conference

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
ANIP

ANI Pharmaceuticals announced that CEO Nikhil Lalwani will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The event aims to showcase the company's commitment to innovative therapeutics and growth across its Rare Disease, Generics, and Brands business sectors.

ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
ANIP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • ANI Pharmaceuticals is presenting at a prominent healthcare industry conference, enhancing visibility with investors and stakeholders.
  • The company focuses on innovative therapeutic areas including ophthalmology, rheumatology, nephrology, neurology, and pulmonology through its Rare Disease business.
  • ANI leverages U.S.-based manufacturing and R&D expertise in its Generics business, contributing to sustainable growth.

PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows:

Date:Wednesday, June 3, 2026 Time:3:45 p.m. ET Webcast:Click Here 

The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.


Risks

  • Market reception to the conference presentation may not significantly impact investor sentiment or share price.
  • Competitive pressures in pharmaceutical sectors such as Rare Disease and Generics could limit growth prospects.
  • Regulatory and operational challenges in manufacturing and commercialization may impact the company's performance.

More from Press Releases

Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation Jun 8, 2026 Snow Rothschild Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering Jun 8, 2026 Cal-Maine Foods to Participate in D.A. Davidson Technology & Consumer Conference Jun 8, 2026 Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 Jun 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 Jun 8, 2026